ArticleAmerican journal of translational research2017
LncRNA EWSAT1 promotes ovarian cancer progression through targeting miR-330-5p expression.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Clinicopathological and prognostic significance of long non-coding RNA EWSAT1 in human cancers: A review and meta analysis.PloS one · 2022Pooled it
- CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway.Journal of ovarian research · 2026Article
- Circulating long non-coding RNANon-coding RNA research · 2024Article
- miR-153-3p suppresses the differentiation and proliferation of neural stem cells via targeting GPR55.Aging · 2023Article
- Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.Frontiers in immunology · 2023Article
- Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11.Disease markers · 2022Article
- LncRNA EWSAT1 Regulates the Tumorigenesis of NSCLC as a ceRNA by Modulating miR-330-5p/ITGA5 Axis.Biochemical genetics · 2021Article
- Long non-coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA-155-5p/tyrosinase-related protein 1 axis.Experimental and therapeutic medicine · 2021Article
- LncRNA PTTG3P induced aberrant glycosylated IgA1 production and B cell growth in IgA nephropathy.Environmental science and pollution research international · 2021Article
- Long non-coding RNA EWSAT1 promoted metastasis and actin cytoskeleton changes via miR-24-3p sponging in osteosarcoma.Journal of cellular and molecular medicine · 2021Article
- LncRNA EWSAT1 Promotes Colorectal Cancer Progression Through Sponging miR-326 to Modulate FBXL20 Expression.OncoTargets and therapy · 2021Article
- Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes.Frontiers in oncology · 2021Article
- LncRNA LINC00473 promoted colorectal cancer cell proliferation and invasion by targeting miR-195 expression.American journal of translational research · 2021Article
- Knockdown of circular RNA hsa_circ_0003204 inhibits oxidative stress and apoptosis through the miR-330-5p/Nod2 axis to ameliorate endothelial cell injury induced by low-density lipoprotein.Central-European journal of immunology · 2021Article
- The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.Frontiers in immunology · 2021Article
- LncRNA EWSAT1 upregulates CPEB4 via miR-330-5p to promote cervical cancer development.Molecular and cellular biochemistry · 2020Article
- Long non-coding RNA EWSAT1 contributes to the proliferation and invasion of glioma by sponging miR-152-3p.Oncology letters · 2020Article
- Long noncoding RNA LINC00461 induced osteoarthritis progression by inhibiting miR-30a-5p.Aging · 2020Article
- Silencing Long Non-coding RNA LINC01224 Inhibits Hepatocellular Carcinoma Progression via MicroRNA-330-5p-Induced Inhibition of CHEK1.Molecular therapy. Nucleic acids · 2020Article
- LINC00311 promotes cancer stem-like properties by targeting miR-330-5p/TLR4 pathway in human papillary thyroid cancer.Cancer medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer ranks as the fifth common tumour in women and is the leading cause of cancer-related death among the women. Long non-coding RNAs (lncRNAs) play crucial roles in the development of tumors. However, the expression and the role of EWSAT1 in ovarian tumor are still unknown. In our study, we found the expression of EWSAT1 was upregulated in ovarian cancer cell lines and samples. Ecoptic expression of EWSAT1 suppressed miR-330-5p expression in ovarian cancer cell. In addition, the expression of miR-330-5p was downregulated in ovarian cancer cell lines and samples. Moreover, the expression of miR-330-5p was negatively related with the expression of EWSAT1 in ovarian cancer samples. Furthermore, we identified Pdia3 was a direct target gene of miR-330-5p. Ecoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell. In addition, Ecoptic expression of miR-330-5p promoted ovarian cancer cell proliferation, colony formation and invasion. Overexpression of EWSAT1 increased ovarian cancer cell proliferation, colony formation and invasion through targeting miR-330-5p. These data suggested that EWSAT1 might act as an oncogene in the development of ovarian cancer partly through inhibiting miR-330-5p expression.
Indexed as
Identifiers
28979684PMC5622253W2983241708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.